Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen

Clinical Laboratory

Volumn 55, Issue 1-2, 2009, Pages 1-7

  Sauerbrei, Andreas ^a   Wutzler, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Fluorescent anti body to membrane antigen test; Gp specific enzyme linked immunosorbent assay; Immune status; Varicella zoster virus

Indexed keywords

CHICKENPOX VACCINE; IMMUNOGLOBULIN G; MEMBRANE ANTIGEN; VARICELLA ZOSTER VACCINE; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HERPES ZOSTER; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; SENSITIVITY AND SPECIFICITY; SEROLOGY; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS ENVELOPE; VIRUS IMMUNITY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOGLOBULIN G; INFANT; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; VIRAL ENVELOPE PROTEINS;

HUMAN HERPESVIRUS 3;

EID: 63049139043     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gershon A.A. The current status of live attenuated varicella vaccine. Arch Virol 2001; 17(Suppl): 1-6
2. Ständige Impfkommission am Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2004. Epidemiol Bull 2004; 30:235-50
3. Oxman MN. Vaccination to prevent herpes zoster and postherpetic neuralgia. Hum Vaccin 2007; 3:64-8
4. Sauerbrei A, Eichhorn U, Schacke M, Wutzler P. Laboratory diagnosis of herpes zoster. J Clin Virol 1999; 14: 31-6
5. Schmutzhard J, Merete RH, Zweyberg WB, Grillner L. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol 2004; 29: 120-6
6. Kempf W, Meylan P, Gerber S et al. for the Swiss Herpes Management Forum. Swiss recommendations for the management of varicella zoster virus infections. Swiss Med Wkly 2007; 137: 239-51
7. Hayward AR, Zerbe GO, Levin MJ. Clinical application of responder cell frequency estimates with four years of follow up. J Immunol Methods 1994; 170: 27-36
8. Weinberg A, Hayward AR, Masters HB, Ogu IA, Levin MJ. Comparison of two methods for detecting varicella-zoster virus antibody with varicella-zoster virus cell-mediated immunity. J Clin Microbiol 1996; 34: 445-6
9. Sauerbrei A, Wutzler P. Varicella-zoster virus infections during pregnancy: epidemiology, clinical symptoms, diagnosis, prevention and therapy. Curr Pediat Rev 2005; 1: 205-16
10. Gallagher J, Quaid B, Cryan B. Susceptibility to varicella-zoster virus infection in health care workers. Occup Med 1996; 46: 289-92
11. Morales-Castill, ME, Alvarez-Munoz MT, Solorzano-Santos F, Gonzalez-Robledo R, Jasso-Gutierrez L, Munoz-Hernandez O. Live varicella vaccine in both immunocompromised and healthy children. Arch Med Res 2000; 31: 85-7
12. Sauerbrei A, Wutzler P. Varicella-Zoster-Virus-Infektionen: Aktuelle Prophylaxe und Therapie. 2nd ed. Bremen London Boston: Uni-Med, 2007
13. Hammond O, Wang Y, Green T et al. The optimizing and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol 2006; 78:1679-87
14. Krah DL. Assays for antibodies to varicella-zoster virus. Infect. Dis Clin North Am 1996; 10: 507-27
15. Wasmuth EH, Miller W. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32: 189-93
16. Li S, Chan IS, Matthews H et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis 2002; 21: 337-42
17. Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Fragen und Antworten zu verschiedenen Impfungen. Epidemiol Bull 2001; 8:58
18. Zaia JA, Oxman MN. Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells. J Infect Dis 1977; 156: 519-30
19. Sauerbrei A, Färber I, Brandstädt A, Schacke M, Wutzler P. Immunofluorescence test for highly sensitive detection of varicellazoster virus-specific IgG - alternative to fluorescent antibody to membrane antigen test. J Virol Methods 2004; 119: 25-30
20. Sauerbrei A, Wutzler P. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. J Clin Microbiol 2006; 44: 3094-7
21. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A. Sero-prevalence of varicella-zoster virus in the German population. Vaccine 2002; 21: 121-4
22. Sauerbrei A, Eichhorn U, Hottenrott G, Wutzler P. Virological diagnosis of herpes simplex encephalitis. J Clin Virol 2000; 17: 31-6
23. Altman DG, Bland JM. Diagnostic tests 1: Sensitivity and specificity. Brit Med J 1994; 308: 1552
24. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. Brit Med J 1994; 309: 102
25. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20: 37-46
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74
27. Aly NY, Al Obaid I, Al-Qulooshi N, Zahed Z. Occupational related outbreak of chickenpox in an intensive care unit. Med Princ Pract 2007; 16: 399-401
28. Kim DH, Messner H, Minden M. et al. Factors influencing varicella zoster virus infection after allogenic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pretransplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10: 90-8
29. Shahbazian H, Ehsanpour A. An outbreak of chickenpox in adult renal transplant recipients. Exp Clin Transplant 2007; 5: 604-6
30. Appisarnthanarak A, Kitphati R, Tawatsupha P, Thongphubeth K, Apisarnthanarak P, Mundy LM. Outbreak of varicella-zoster virus infection among health care workers. Infect Control Hosp Epidemiol 2007; 28: 430-4
31. Robert Koch-Institut. Zur Seroprävalenz gegen Varicella-Zoster-Virus und zur Verlässlichkeit anamnestischer Angaben. Epidemiol Bull 2003; 43: 347
32. Watson B, Civen R, Reynolds M. et al. Validity of self-reported varicella disease history in pregnant women attending prenatal clinics. Public Health Rep 2007; 122: 499-506
33. Provost PJ, Krah DL, Kuter BJ et al. Antibody assay suitable for assessing immune responses to live varicella vaccine. Vaccine 1991;9: 111-6
34. Ndumbe PM, Cradock-Watson J, Levinski RJ. Natural and artificial immunity to varicella-zoster virus. J Med Virol 1988; 25: 171-8
35. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gp-ELISA and neutralizing antibody responses to Oka/Merck live vaccine (Varivax) in children and adults. Vaccine 1997; 15: 61-4